Volume 2.48 | Dec 5

Pulmonary Cell News 2.48 December 5, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Human Stem Cells Converted to Functional Lung Cells
Scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance has significant potential for modeling lung disease, screening drugs, studying human lung development, and, ultimately, generating lung tissue for transplantation. [Press release from Columbia University Medical Center discussing online prepublication in Nature Biotechnology] Press Release | Abstract
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
 
PUBLICATIONS (Ranked by impact factor of the journal)
Toxicity Evaluation of Engineered Nanoparticles for Medical Applications Using Pulmonary Epithelial Cells
The effects of poly(lactic-co-glycolic acid), silica, iron oxide and titanium dioxide nanoparticles were studied using human bronchial and alveolar epithelial cells. Scientists evaluated cytotoxicity, reactive oxygen species production and pro-inflammatory response in both cell lines. [Nanotoxicology] Abstract

Intracellular Accumulation Dynamics and Fate of Zinc Ions in Alveolar Epithelial Cells Exposed to Airborne ZnO Nanoparticles at the Air-Liquid Interface
To determine the precise intracellular accumulation dynamics and fate of zinc ions shed by airborne nanoparticles (NPs) in the cellular environment, researchers exposed alveolar epithelial cells to aerosolized NPs at the air-liquid interface. [Nanotoxicology] Abstract

Hyperoxia Increases the Elastic Modulus of Alveolar Epithelial Cells Through Rho Kinase
Scientists examined cytoskeletal structures in cultured murine lung alveolar epithelial cells under normoxic and hyperoxic conditions. They also measured cell elasticity using atomic force microscopy in the indenter mode. [FEBS J] Abstract

Comparison of Tobacco-Containing and Tobacco-Free Waterpipe Products: Effects on Human Alveolar Cells
Researchers compared the effects of smoke generated using tobacco-free and conventional tobacco-derived products on human alveolar cells. They found that smoke from both types of waterpipe products markedly reduced cell proliferation, caused cell cycle arrest at G0/G1, and increased cell doubling time. [Nicotine Tob Res] Abstract

Expansive Generation of Functional Airway Epithelium from Human Embryonic Stem Cells
Researchers reveal the potential of human embryonic stem cell to produce multipotent lung progenitors using a combined growth factor and physical culture approach, guided by the use of novel markers LIFRα and NRP1. [Stem Cells Transl Med] Abstract

LUNG CANCER

Targeting SOD1 Reduces Experimental Non-Small-Cell Lung Cancer
Investigators report that inhibition of superoxide dismutase 1 (SOD1) by the small molecule ATN-224 induced cell death in various non-small-cell lung cancer cells, including those harboring KRAS mutations. [J Clin Invest] Full Article | Press Release

Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
The 8p12 locus is frequently amplified in squamous-cell lung cancer. Researchers found that, in contrast to other recurrent amplifications, the 8p12 region included multiple centers of amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands in vitro and in vivo. [Cancer Discov] Abstract

Gambogic Acid Synergistically Potentiates Cisplatin-Induced Apoptosis in Non-Small-Cell Lung Cancer through Suppressing NF-κB and MAPK/HO-1 Signaling
Scientists investigated whether gambogic acid (GA) would be synergistic with cisplatin (CDDP) against non-small-cell lung cancer. Cell viability results showed that sequential CDDP-GA treatment resulted in a strong synergistic action in A549, NCI-H460, and NCI-H1299 cell lines, whereas the reverse sequence and simultaneous treatments led to a slight synergistic or additive action. [Brit J Cancer] Abstract

A Novel Compound RY10-4 Induces Apoptosis and Inhibits Invasion via Inhibiting STAT3 through ERK-, p38-Dependent Pathways in Human Lung Adenocarcinoma A549 Cells
Treatment with RY10-4 inhibited the expression of pro-caspase-3, pro-caspase-9, Bcl-2 as well as phosphorylation of Signal transducer and activator of transcription-3 (p-STAT3). It also reduced the expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and increases the expressions of reversion-inducing cysteine-rich protein with kazal motifs, as well as tissue inhibitor of metalloproteinase via inhibiting STAT3 by activating the mitogen-activated protein kinases in A549 cells treated with RY10-4. [Chem Biol Interact] Abstract

Activation of Peroxisomal Proliferator Activated Receptor (PPAR)α Is Beneficial for the Prevention and Treatment of Non-Small Cell Lung Cancer
Researchers showed that targeting the formation of pro-angiogenic epoxyeicosatrienoic acids by the cytochrome P450 arachidonic acid epoxygenases represents a new and safe mechanism to treat non-small cell lung cancer growth and progression. [Cancer Res] Abstract

Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
 
REVIEWS
Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
Crizotinib is the standard of care in terms of the treatment of patients with anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer; while the current EU approval is for second (or subsequent)-line use only, the first-line use of the drug is being evaluated in ongoing Phase III studies. [Drugs] Abstract

Adult Asthma Biomarkers
A variety of novel asthma treatments have been developed based on phenotypes, and the clinical trial results show promising responses. This review summarizes the current knowledge of biomarkers for the determination of asthma phenotypes. [Curr Opin Allergy Clin Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
One of a Kind People Powered CT Donation Program for Lung Cancer Research Expands
Lung Cancer Alliance and Siemens Healthcare announced the national expansion of Give A Scan, the first computed tomography (CT) donation program that allows people to donate directly to lung cancer research, by asking patients and their loved ones to Give A Scan. The donated CT scans are stripped of personal identifiers and then put on the Give a Scan website along with the donated clinical data in open access and at no charge to researchers around the world. [Lung Cancer Alliance] Press Release

3-V Biosciences Commences Patient Dosing in Phase I Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
3-V Biosciences, Inc. announced the recent initiation of a Phase I clinical study of TVB-2640 in patients with advanced solid tumors. In a series of preclinical studies, 3-V’s FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers. [3-V Biosciences, Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
Canada’s Progress in Tobacco Control under Threat
A new report reveals that Canada is at risk losing ground in its efforts to reduce tobacco use. The study finds that cigarettes became more affordable in Canada between 2002 and 2010 and pictorial health warnings are noticed less by smokers. [PR Newswire Association LLC] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposia: Inflammation, Infection and Cancer
March 9-14, 2014
Whistler, Canada

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

NEW Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

NEW Assistant Professor, Associate Professor, Professor – Lung Biology or Pulmonary and Critical Care Diseases (Boston University School of Medicine & Boston Medical Center)

NEW Associate Scientist II/Scientist I – Respiratory, Autoimmunity and Inflammation Research (MedImmune)

PhD Position – Genetics of Non-Smoker Chronic Obstructive Pulmonary Disorders (Göttingen Center for Molecular Biosciences)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Pulmonary Cell News: Archives | Events | Contact Us